Contents

SECTION I. Drug Discovery

Introduction
JOHN F. RYLEY 1

CHAPTER 1

Drug Discovery: A Chemist's Approach
F. THOMAS BOYLE. With 8 Figures 3

A. Introduction 3
B. Development of a Lead 4
C. Identification of a Lead 14
I. Fungal Sterol Metabolism — A Target for Lead Identification . . 14
II. Δ_{24}–Transmethylation in Yeast and Fungal Sterol Synthesis . . . 18
III. Regulation of Δ_{24}–Transmethylation 19
IV. In House Lead Structure Selection and Biological Investigations 21
D. Concluding Remarks 27
References 28

CHAPTER 2

Drug Discovery: A Biochemist's Approach
DAVID KERRIDGE and HUGO VANDEN BOSSCHE. With 10 Figures 31

A. Introduction 31
B. Factors Affecting the Choice of Target 34
I. The Cell Wall as a Barrier to Drug Uptake 35
C. Potential Targets 36
I. External to the Plasma Membrane 36
1. Structural Polysaccharides 36
2. Cell Wall Associated Enzymes 37
3. Plasma Membrane Associated Targets 39
II. Internal Targets 45
1. Transport of Drugs into Sensitive Fungi 45
2. Plasma Membrane Proteins 48

Bibliografische Informationen
http://d-nb.info/900274131

digitalisiert durch DEUTSCHE NATIONAL BIBLIOTHEK

3. Pathways of Intermediary Metabolism 56
4. Macromolecular Synthesis 62
III. Miscellaneous Targets 63
1. Drugs Preventing Adhesion 63
2. Dimorphism 64
3. The Cytoskeleton 64
4. Exocellular Compounds Involved in Disease 65
IV. Which Target? 65
D. Short-Term Solutions to Antifungal Therapy 66
I. Combination Therapy 66
II. Drug Formulation 67
E. Long-Terms Developments 67
References 68

CHAPTER 3

Drug Discovery: Nature's Approach
MANUEL DEBONO and ROBERT S. GORDEE. With 2 Figures 77

A. Introduction 77
B. Sources of Samples for Screening 78
I. Soil 78
II. Marine Organisms 87
C. The Fungal Cell Wall as an Antifungal Target 90
I. Biomolecular Composition and Approaches to Screening for Inhibition of Cell Wall Biosynthesis 90
II. Inhibition of β-(1,3)-Glucan Synthesis 92
III. Inhibitors of Chitin Synthase 95
D. Biological Evaluation of Antifungal Agents 99
E. Conclusion 102
References 103

CHAPTER 4

Screening and Evaluation In Vitro
ROBERT G. WILSON and JOHN F. RYLEY 111

A. Purpose of Screening 111
B. Methods of Screening 112
C. Choice of Organisms and Conditions 113
D. Choice of Media 113
E. A Workable In Vitro Screen 115
F. Interpretation of Screen Results 117
G. Relevance of Screen 117
H. Evaluation In Vitro 120
J. Features of Activity 122

K. Conclusions 126
References 127

CHAPTER 5

Screening and Evaluation In Vivo
JOHN F. RYLEY. With 2 Figures 129

A. Preliminary Considerations 129
B. Types of Screen 130
C. The Multi-Infection Screen 131
D. Further Evaluation 134
I. Candidosis 134
1. Rat Vaginitis 134
2. Intestinal Infections 135
3. Systemic Infections 135
4. Skin Infections 136
5. Other Infections 138
II. Dermatophytosis 139
III. Cryptococcosis 140
IV. Aspergillosis 142
V. Other Mycoses 142
1. Coccidioidomycosis 142
2. Paracoccidioidomycosis 143
3. Histoplasmosis 143
4. Blastomycosis 143
5. Sporotrichosis 144
6. Miscellaneous Mycoses 144
E. Extrapolation to Clinical Use 145
References 145

SECTION II. Drug Development

Introduction
JOHN F. RYLEY 149

CHAPTER 6

Mode of Action Studies
ANNEMARIE POLAK. With 12 Figures 153

A. Introduction 153
B. Target: Nucleic Acid Synthesis and Cell Division 155
I. 5-Fluorocytosine 155
II. Griseofulvin 159

C. Target: Cell Membrane 160
I. Polyene Macrolides 161
II. Ergosterol Biosynthesis Inhibitors 164
1. Imidazole and Triazole Derivatives 164
2. Morpholine Derivatives 168
3. Allylamines 170
4. Thiocarbamate Antifungals 172
5. Conclusions 173
D. Target: Cell Wall Synthesis 173
I. Chitin Synthase Inhibition 174
II. Glucan Synthesis 175
References 179

CHAPTER 7

Pharmacokinetic Aspects of Antifungal Therapy
MICHAEL H. TARBIT. With 3 Figures 183

A. Introduction 183
B. Pharmacokinetic and Metabolic Concepts 183
I. In Vitro Potency Versus In Vivo Efficacy 184
II. Analysis of Samples 184
III. Assessment of Absorption and Systemic Availability 185
IV. Distribution Parameters 187
V. Assessment of Duration of Action 189
VI. Summary 191
C. Pharmacokinetics of Clinically Used Antifungal Agents 191
I. Non-Azoles 192
1. Amphotericin B 192
2. 5-Fluorocytosine 193
II. First Generation Imidazole Drugs 193
III. Ketoconazole 195
IV. Novel Triazole Agents 197
D. Conclusions 200
References 200

CHAPTER 8

Hepatic and Endocrine Effects of Azole Antifungal Agents
MICHAEL H. TARBIT, WILLIAM R. ROBERTSON, and ANN LAMBERT
With 5 Figures 205

A. Introduction 205
B. Nature of Cytochrome P-450 206
C. Mode of Interaction of Azoles with Cytochrome P-450 207
D. Effects of Azoles on Mammalian Hepatic Cytochromes P-450 209

I. In Vitro Metabolism Studies 209
II. In Vivo Drug Interaction Studies 211
III. Induction of Cytochromes P-450 213
E. Endocrine Effects of Azoles 215
I. Mammalian Endocrine System 215
II. Effects of Ketoconazole on Steroidogenic Tissues 216
III. Other Endocrine Effects of Ketoconazole 218
IV. Effect of Other Imidazole Antifungal Agents on Steroidogenesis 219
V. New Antifungal Agents 220
VI. Clinical Use of Ketoconazole in Endocrinology 220
1. Use in Cortisol Overproduction 220
2. Use in Androgen Overproduction 220
3. Other Clinical Uses 221
VII. Assessment of Anti-Steroidogenic Biopotency and Site of Action of Antifungal Agents 221
F. Conclusions 222
References 223

CHAPTER 9

Structure-Teratogenicity Relationships Among Antifungal Triazoles
OLIVER P. FLINT and F. THOMAS BOYLE. With 6 Figures 231

A. Introduction 231
B. Materials and Methods 231
C. Results 232
I. In Vitro Assays 232
II. In Vivo Teratogenicity 236
1. Monotriazole Tertiary Alcohols 236
2. Bistriazole Tertiary Alcohols 239
D. Discussion 239
I. Monotriazole Tertiary Alcohols 240
II. Bistriazole Tertiary Alcohols 243
III. Correlation Between IC_{50T} and In Vivo Teratogenicity 245
1. Monotriazole Tertiary Alcohols 245
2. Bistriazole Tertiary Alcohols 246
E. Conclusions 247
References 248

CHAPTER 10

Formulation
HEINZ HÄNEL and WOLFGANG RITTER. With 8 Figures 251

A. Introduction 251

B. Topical Formulations 251
I. Skin Infections 251
1. Penetration Studies 252
2. Therapeutic Studies 258
3. Pharmacokinetic Studies 261
II. Nail Infections 265
1. In Vitro Models 265
III. Vaginal Infections 269
1. Absorption Studies 270
2. Therapeutic Studies 271
C. Oral Formulations 271
D. Parenteral Formulations 272
References 274

CHAPTER 11

Regulatory Procedures
SARAH C. EARDLEY. With 4 Figures 279

A. Introduction 279
B. A Short History and Some of the Landmarks in Drug Development and Regulation 280
I. Early Days 280
II. The Development of the Pharmacopoeias 281
III. The Rise of the Pharmaceutical Industry 282
IV. Self-Medication, Patent Medicines and Secret Remedies 283
V. Poisons and Dangerous Drugs 284
VI. The Therapeutic Substances Act 284
VII. Thalidomide and After 285
VIII. Evolution of Regulatory Procedures in the USA 285
IX. Summary 287
C. Who Is Involved? The Regulators and the Regulated 288
D. Data Requirements for a New Drug 289
E. The Regulatory Process: Pre-Submission 289
I. The Activities and the Time Scale 291
II. The Cost 293
III. The Scale of the Marketing Application 295
IV. Compiling the Marketing Application 295
V. Structuring the Marketing Application 296
VI. Expert Reports 298
VII. 'Second Wave' Countries 299
F. The Regulatory Process: Post-Submission 299
I. Processing of a Marketing Application Within the UK Department of Health 299

II. The Committee for Proprietary Medicinal Products 303
III. The Regulatory Process in 'Second Wave' Countries 306
G. Regulatory Processes for Marketed and Older Products 306
I. Supplementary Applications 307
II. Drug Review Programmes 307
III. Maintaining the Consistency of Prescribing Information 307
H. Discussion 308
References 311

CHAPTER 12

Clinical Trials

THOMAS C. JONES and JOHN J. STERN 313

A. Introduction 313
B. Why Clinical Trials Exist 314
C. General Principles in the Study of Antifungal Drugs 316
I. Evaluation of Drug Efficacy in Epidermal and Mucosal Mycotic Infections 316
1. What is the Meaning of the Mycological Test? 317
2. How Can Signs and Symptoms Best be Evaluated? 318
3. What is the Significance of and Best Way to Evaluate Relapse or Reinfection? 318
II. Evaluation of Drug Efficacy in Systemic Mycoses 319
III. Documentation of Drug Tolerability During Topical Application 320
IV. Documentation of Drug Tolerability During Oral or Intravenous Drug Use 320
D. Organization of Clinical Trials for the Treatment of Dermatomycoses 321
I. Tolerability and Pharmacokinetic Assessment in Healthy Volunteers (Phase I) 322
II. Open-Label Efficacy Trials (Phase I) 322
III. Dose Finding and Duration Finding Studies (Phase II) 322
IV. Exploring Drug Efficacy and Tolerability in Various Diseases (Phase III) 323
V. Evaluation of Special Features of the Drug; Profiling Studies (Phase IV) 323
E. Special Aspects of Clinical Trials in the Treatment of Systemic Mycoses 323
F. Statistical Issues in the Conduct of Clinical Trials 326
G. Selected Issues in Protocol and Investigator Brochure Preparation, Good Clinical Practice Implementation, and Final Study Report Documentation 329

I. Protocol and Investigator Brochure Preparation 329
II. Good Clinical Practice Implementation 330
III. Final Study Report Documentation 330
H. Summary and Conclusions 330
References 331

SECTION III. Clinical Usage

Introduction
JOHN F. RYLEY 333

CHAPTER 13

Clinical Usage — A Dermatologist's Viewpoint
MARGUERITE M. ROBERTS 335

A. Introduction 335
B. The Superficial Mycoses 335
I. Dermatophyte Infection 335
1. Aetiology and Epidemiology 335
2. Clinical Features 336
3. Differential Diagnosis 337
4. Laboratory Diagnosis 338
5. Treatment 338
II. Superficial and Mucocutaneous Candidosis 340
1. Aetiology and Epidemiology 340
2. Clinical Features 340
3. Differential Diagnosis 341
4. Laboratory Diagnosis 342
5. Treatment 342
III. Pityriasis Versicolor 343
1. Aetiology and Epidemiology 343
2. Clinical Features 344
3. Differential Diagnosis 344
4. Laboratory Diagnosis 344
5. Treatment 344
IV. Less Common Superficial Fungal Infections of Nails 345
1. Aetiology and Epidemiology 345
2. Clinical Features 345
3. Differential Diagnosis 346
4. Laboratory Diagnosis 346
5. Treatment 346
V. Less Common Superficial Fungal Infections of Skin and Hair .. 347

1. Aetiology and Epidemiology 347
2. Clinical Features 347
3. Differential Diagnosis 347
4. Laboratory Diagnosis 347
5. Treatment 348
VI. Otomycosis 348
1. Aetiology and Epidemiology 348
2. Clinical Features 348
3. Differential Diagnosis 348
4. Laboratory Diagnosis 348
5. Treatment 348
C. The Subcutaneous Mycoses 349
I. Mycetoma 349
1. Aetiology and Epidemiology 349
2. Clinical Features 349
3. Differential Diagnosis 350
4. Laboratory Diagnosis 350
5. Treatment 350
II. Chromomycosis 350
1. Aetiology and Epidemiology 350
2. Clinical Features 351
3. Differential Diagnosis 351
4. Laboratory Diagnosis 351
5. Treatment 351
III. Sporotrichosis 352
1. Aetiology and Epidemiology 352
2. Clinical Features 352
3. Differential Diagnosis 352
4. Laboratory Diagnosis 352
5. Treatment 353
IV. Phaeohyphomycosis 353
1. Aetiology and Epidemiology 353
2. Clinical Features 353
3. Differential Diagnosis 353
4. Laboratory Diagnosis 353
5. Treatment 353
V. Lobomycosis 354
1. Aetiology and Epidemiology 354
2. Clinical Features 354
3. Differential Diagnosis 354
4. Laboratory Diagnosis 354
5. Treatment 354
VI. Zygomycosis (Phycomycosis) 354
1. Aetiology and Epidemiology 354

2. Clinical Features 354
3. Differential Diagnosis 355
4. Laboratory Diagnosis 355
5. Treatment 355
VII. Rhinosporidiosis 355
1. Aetiology and Epidemiology 355
2. Clinical Features 355
3. Differential Diagnosis 355
4. Laboratory Diagnosis 355
5. Treatment 355
D. Present Therapeutic Practice and Future Needs 356
I. Introduction 356
II. Choice of Preparation 356
1. Introduction 356
2. The Superficial Mycoses 356
3. The Subcutaneous Mycoses 357
III. Factors Influencing Treatment Failure 358
1. Lack of Compliance 358
2. Host Factors 358
3. Fungal Pathogenicity 358
4. Drug Factors 359
5. Inadequate Treatment 359
6. Epidemiological Factors 360
IV. Future Requirements 360
References 361

CHAPTER 14

Therapeutic Considerations in Fungal Vaginitis

JACK D. SOBEL 365

A. Introduction 365
B. Therapeutic Principles 365
I. Topical Agents for Acute Candida Vaginitis 367
1. Polyenes 367
2. Azoles 367
II. Status of Short Course Topical Therapy 369
III. Oral Systemic Agents for Candida Vaginitis 370
C. Chronic and Recurrent Vulvovaginal Candidosis 371
I. Pathogenesis of Recurrent Vulvovaginal Candidosis 372
II. Treatment of Recurrent and Chronic Candida Vaginitis 374
III. Resistance to Antimycotic Agents 376
D. Acute Vaginitis in Pregnancy 377
E. Management of Sexual Partners of Women with Vulvovaginal Candidosis 377

F. Therapeutic Caveats in Vulvovaginal Candidosis 378
G. Summary 379
References 380

CHAPTER 15

An Infectious Disease Specialist's Viewpoint

ALAN M. SUGAR 385

A. Introduction 385
B. The Problem 386
C. Diagnosis 387
D. Therapy 388
E. Prospect for Vaccines 392
F. The Future 393
References 394

CHAPTER 16

Management of Fungal Infections in Patients with Neoplastic Diseases

THOMAS J. WALSH and PHILIP A. PIZZO 399

A. Introduction 399
B. Principles of Host Defense in Patients with Neoplastic Diseases 399
C. Definitions and Classification of Nosocomial Fungal Infections 400
I. Aspergillosis 401
1. Microbiology 401
2. Hospital Epidemiology 401
3. Clinical Manifestations 403
4. Treatment 404
II. Zygomycosis 406
1. Microbiology 406
2. Hospital Epidemiology 406
3. Clinical Manifestations 406
4. Treatment 407
III. Other Type I (Hospital-Acquired) Nosocomial Fungal Infections in Cancer Patients 407
1. Pseudallescherosis 407
2. Fusariosis 407
3. Phaeohyphomycosis 408
IV. Candidosis 408
1. Microbiology 408
2. Hospital Epidemiology 408
3. Clinical Manifestations 409
4. Treatment 412

V. Trichosporonosis 413
VI. Malassezia furfur Fungemia 413
VII. Reactivation of Latent Fungal Infections 414
VIII. Fungal Infections in Patients with Combined Neoplastic Diseases and AIDS 414
D. Future Directions 414
References 415

CHAPTER 17

Fungal Infections and AIDS
BERTRAND DUPONT 421

A. Introduction 421
B. Candidosis 421
C. Cryptococcosis 425
D. Histoplasmosis 430
E. Coccidioidomycosis 431
F. Dermatophytes 432
G. Seborrhoeic Dermatitis 433
H. Other Mycoses 433
References 433

CHAPTER 18

Older Drugs
DONALD ARMSTRONG and HEINZ J. SCHMITT 439

A. Introduction 439
B. Amphotericin B 439
I. History 439
II. Mode of Action 440
III. Resistance 441
IV. Pharmacokinetics 442
V. Indications 444
VI. Administration 445
VII. Toxicity 446
C. 5-Fluorocytosine 447
I. History 447
II. Mode of Action 447
III. Resistance 448
IV. Pharmacokinetics 449
V. Indications 449
VI. Administration 450
VII. Toxicity 450
References 450

CHAPTER 19

Systemic Azole Antifungal Drugs — Into the 1990s

JOHN R. GRAYBILL 455

A. The Evolution of Azole Antifungals in Clinical Use 455
I. Introduction: Why Not Stay with 'Good Old' Amphotericin B? 455
II. The Dawn of the Era of Azole Antifungals 455
1. The First Efforts 'Fail' — Clotrimazole 457
2. The Potential Is Demonstrated — Miconazole 457
III. The Dam Breaks with Ketoconazole 459
IV. The 'Second Generation' Azoles 461
1. Itraconazole — Broad Spectrum with Less Toxicity 461
2. Fluconazole — Targeting a Disease Based on Preclinical Studies 462
3. SCH39304 — Potent 'New Kid on the Block' 463
V. Further out on the Horizon 464
1. BAYER 3783 464
2. Saperconazole — Son of Itraconazole 464
VI. A Drug that was Retired Before Its Time — ICI 153,066 464
B. Interrelation of the Azoles 464
C. Patterns of Use of the Antifungal Azoles in the 1990s 465
I. Use in Neutropenic Patients 465
1. Treatment of Established Candidosis and Aspergillosis 465
2. Empiric Antifungal Therapy for Candidosis and Aspergillosis 465
3. Prophylaxis of Candidosis and Aspergillosis 466
II. Use in Fungal Infections in Other Immunocompromised States 467
1. AIDS 467
2. Cryptococcosis 469
III. Use in Nonimmunocompromised Patients 469
1. Major Endemic Mycoses 469
2. Miscellaneous Mycoses 472
D. Summary 475
References 475

CHAPTER 20

Terbinafine

THOMAS C. JONES and VIOLETTE V. VILLARS. With 6 Figures 483

A. Introduction 483
B. Chemistry and Mode of Action 483

I. Chemistry 483
II. Mode of Action 485
III. Measurement of Terbinafine in Plasma, Body Fluids and Tissue 486
C. Antifungal Activity 487
I. Fungicidal and Fungistatic Actions 487
II. Morphological Effects of Terbinafine on Fungi 488
III. Spectrum of Antifungal Activity 490
D. Activity in Animals 491
I. Metabolism 491
II. Antifungal Activity 492
E. Toxicology 493
I. Acute and Chronic Toxicity 493
II. Fertility, Reproduction, Teratogenicity and Mutagenicity 494
F. Clinical Results; Efficacy and Tolerability 495
I. Pharmacokinetics in Humans 495
II. Efficacy of Terbinafine 495
III. Tolerability of Oral and Topical Terbinafine 499
G. Summary 501
References 501

CHAPTER 21

Amorolfine
ANNEMARIE POLAK and MICHEL ZAUG. With 7 Figures 505

A. Introduction 505
B. Preclinical Results 505
I. Antifungal Activity of Amorolfine In Vitro 505
1. Fungistatic Activity 505
2. Fungicidal Activity 507
II. Therapeutic Efficacy in Animal Models 507
1. Deep Mycoses 507
2. Topical Mycoses 508
C. Clinical Studies 511
I. Human Pharmacokinetics 511
1. Dermal Penetration 511
2. Vaginal Absorption 512
II. Human Pharmacology 512
1. Persistence in the Skin 512
2. Dermal Tolerance 513
3. Persistence Under the Nail 513
4. Vaginal Tolerance 515
III. Therapeutic Trials 515
1. Dermatomycosis 515

2. Onychomycoses 517
3. Vulvovaginal Mycosis 517
IV. Conclusion 520
References 520

SECTION IV. Where Next?

Introduction
JOHN F. RYLEY 523

CHAPTER 22

Other Compounds in Development
JOHN F. RYLEY with ROBERT S. GORDEE and DAVID LOEBENBERG 525

A. Cilofungin 525
I. Antifungal Activity In Vitro 525
II. Antifungal Activity In Vivo 527
III. Mode of Action 528
IV. Toxicology 528
V. Pharmacokinetics 529
VI. Current Status 529
B. SCH 39304 (SM 8668) 530
I. Antifungal Activity In Vitro 530
II. Antifungal Activity In Vivo 531
III. Pharmacokinetic Studies in Animals 533
IV. Current Status 534
C. ICI 195,739 534
I. Antifungal Activity In Vitro 534
II. Antifungal Activity In Vivo 536
III. Mode of Action Studies 538
IV. Pharmacokinetics and Toxicology 540
D. Other Azoles 540
I. Saperconazole 540
II. SDZ 89-485 541
III. BAY R 3783 (Electrazole) 542
E. Non-Azoles 544
I. SDZ 87-469 544
II. BMY 28567 (Pradimycin) 544
III. Nikkomycin Z 545
References 546

Subject Index 551